Literature DB >> 31134360

In reply to Swain et al.: Re-evaluation of updated meta-analysis including trials RTOG 1016 and De-ESCALaTE.

Petar Suton1, Marko Skelin2, Zoran Rakusic3, Stjepan Dokuzovic4, Ivica Luksic5.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 31134360     DOI： 10.1007/s00405-019-05485-7

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN： 0937-4477            Impact factor:   2.503


× No keyword cloud information.
  3 in total

1.  Cisplatin-based chemoradiotherapy trumps cetuximab-based bioradiotherapy in p16/HPV-positive oropharyngeal cancers.

Authors:  Monali Swain; Tejpal Gupta; Sadhana Kannan; JaiPrakash Agarwal
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-04-25       Impact factor: 2.503

2.  Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE.

Authors:  Petar Suton; Marko Skelin; Zoran Rakusic; Stjepan Dokuzovic; Ivica Luksic
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-03-18       Impact factor: 2.503

3.  Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.

Authors:  James A Bonner; Paul M Harari; Jordi Giralt; Nozar Azarnia; Dong M Shin; Roger B Cohen; Christopher U Jones; Ranjan Sur; David Raben; Jacek Jassem; Roger Ove; Merrill S Kies; Jose Baselga; Hagop Youssoufian; Nadia Amellal; Eric K Rowinsky; K Kian Ang
Journal:  N Engl J Med       Date:  2006-02-09       Impact factor: 91.245
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.